Hepatitis B Treatment: Medicines, Monitoring and Care

Hepatitis B treatment depends on whether the infection is recent or long term, how the liver is doing, and the medicines available where you live. ²

This guide explains the decisions behind treatment, what follow-up involves, and the questions worth discussing with your care team.

Chronic hepatitis B may be treated with antivirals that control the virus and help protect the liver. Whether to start treatment and which medicine to use depend on an individual assessment. ⁵

This is general educational information, not a personal diagnosis or prescription. Treatment decisions belong with a qualified healthcare professional who knows your history. Read our medical disclaimer.

For background on the infection itself, see our general hepatitis B guide.

Acute hepatitis B: what treatment involves

A recent, uncomplicated hepatitis B infection is usually managed with supportive care rather than a routine antiviral prescription. Supportive care includes attention to hydration, nutrition, rest, and symptoms while a clinician follows recovery. It is an active care plan, with instructions about reassessment if the illness changes. A person who feels too unwell to drink or manage at home needs clinical advice rather than simply waiting for the infection to pass. ⁴

Severe or prolonged acute hepatitis, particularly acute liver failure, is different. Specialist teams may use antiviral treatment and arrange hospital care. The exception matters: advice that antivirals are never used for acute hepatitis B is misleading. The assessment depends on the severity and course of the illness, not just on when infection was discovered. ²

Tell the clinician about prescription medicines, over-the-counter products, and supplements during an acute illness. Some products can add to liver problems, and the safety of a familiar pain reliever may need reviewing. Avoid alcohol, and ask which symptom treatments are appropriate. Feeling better is useful information, but blood tests and follow-up help establish what is happening to the infection. Symptoms alone cannot show whether hepatitis B has cleared or remains present. ⁵

Who may need treatment for chronic hepatitis B?

For chronic hepatitis B, the decision combines evidence of liver scarring, viral activity, liver inflammation, and factors that can increase risk. The World Health Organization broadened treatment eligibility in its 2024 guidance. Its approach includes significant fibrosis or cirrhosis and recognizes situations such as coinfection, immune suppression, and a family history of cirrhosis or liver cancer. This is why two people with similar viral-load results may receive different advice. A decision should be explained in terms of the person’s overall findings, rather than one highlighted number on a laboratory report. Local guidance and access to testing also influence how that assessment is delivered. ¹

A normal alanine aminotransferase, or ALT, result does not automatically settle the treatment question. The 2025 AASLD/IDSA guideline includes treatment or shared decision-making for selected people previously described as immune tolerant or in an indeterminate phase. These categories describe patterns of results; they are not a reason to stop asking about liver health. Age, disease features, and individual circumstances still need professional interpretation. ²

EASL’s 2025 guidance likewise puts viral activity, liver injury, and fibrosis assessment together. Someone who is not starting medicine still needs an agreed reassessment plan, because the pattern can change over time. Ask what finding would lead the team to reconsider treatment. Monitoring should have a purpose and a next review, rather than becoming an indefinite instruction to wait without explanation. ³

Why earlier treatment is being studied

The ATTENTION trial helps explain why the boundaries of treatment continue to be discussed. It studied selected adults without cirrhosis who had substantial HBV DNA but normal or only mildly increased ALT. Its interim findings raised the possibility of benefit from earlier treatment, but there were few outcome events and the analysis did not cross its prespecified stopping boundary. An interim result is not the same as a definitive answer for every patient. The uncertainty around the estimated treatment effect included the possibility of no difference. A promising direction therefore should not be described as proof of a reduction in clinical events for every eligible person. The trial therefore supports a careful conversation about emerging evidence rather than a rule that everyone with detectable virus must immediately take medicine. It also cannot determine the right choice for someone whose health, liver findings, or circumstances differ from those studied. Clinical guidelines weigh this evidence alongside other studies and the practical consequences of long-term treatment. ²⁴

The tests behind the treatment decision

A liver panel contains several measurements with different jobs. ALT and AST are enzymes that can rise with liver-cell injury. Bilirubin relates to the handling of a waste product, while albumin and clotting measurements can contribute information about liver function. These results are not interchangeable. Prothrombin time measures how long blood takes to clot, while albumin is a protein made in the liver. Including them in an assessment is different from simply repeating an injury enzyme such as ALT. An abnormal result also does not, by itself, identify the cause of the problem. Clinicians interpret the pattern alongside symptoms, medical history, other tests, and changes over time. During treatment, repeat testing can help assess response or look for adverse effects. Ask which measurement the team is following and what a change would mean in your situation. The phrase “liver tests” can otherwise hide several quite different questions, making a report seem either more reassuring or more alarming than its full context supports. ²⁶

Blood tests are only part of an HBV assessment. Elastography can help estimate liver stiffness, and some people need other investigations to assess scarring. A liver biopsy is used in selected circumstances rather than being an automatic requirement for everyone. Many people with chronic infection have no obvious symptoms, so feeling well cannot replace this assessment. It helps to distinguish the tests that identify infection from those that examine its effects on the liver. ⁵

Oral antiviral medicines: how the choice is made

WHO prefers tenofovir disoproxil fumarate or entecavir when long-term treatment is indicated, with tenofovir alafenamide among options in particular kidney or bone circumstances. Older medicines with a low barrier to resistance are not equivalent default choices for long-term monotherapy. A prescription should therefore reflect current guidance as well as previous treatment. ¹

Tenofovir disoproxil fumarate, or TDF

TDF is an oral antiviral used for chronic hepatitis B. Its prescribing information emphasizes kidney assessment and, when relevant, bone health. The team needs to know about kidney problems, fracture risks, and other medicines that could affect the kidneys. These checks help determine suitability and the monitoring plan; they do not mean everyone taking TDF will develop those problems. HIV testing also matters before treatment because HBV management must be coordinated with HIV care if both infections are present. ¹³

Use the instructions for your actual product rather than assuming every hepatitis B tablet is taken the same way. Tell the prescriber if another clinician starts a medicine or if you begin using an over-the-counter product regularly. TDF’s information also warns about hepatitis worsening after discontinuation. If access, tolerability, or a new health issue threatens the treatment plan, contact the prescribing team before an interruption develops. ¹³

Tenofovir alafenamide, or TAF

TAF is another tenofovir-based option, but it is a different formulation from TDF. The US Vemlidy label has its own instructions about food, interacting medicines, kidney assessment, and liver impairment. It should not be treated as a tablet-for-tablet substitute chosen without review. Kidney monitoring still matters, and the medicine is not free of potential adverse effects. The prescriber considers the whole clinical picture rather than choosing solely because one formulation sounds newer. ¹²

For the Vemlidy product, the US label specifies taking it with food. Follow the directions supplied with the medicine you receive and ask a pharmacist to explain any uncertainty. Share a complete medicine and supplement list so interactions can be checked. The label also warns that stopping therapy can lead to serious hepatitis flares. Running out should therefore trigger an early call to the clinic or pharmacy, not an unplanned experiment in whether the medicine is still necessary. ¹²

Entecavir

Entecavir is another oral option, with prescribing decisions affected by kidney function and previous antiviral treatment. In particular, a history of lamivudine use or resistance is relevant, even if that treatment ended years ago. Bring old medicine names or records when possible. HIV status must also be considered: entecavir is not an appropriate stand-alone response to untreated HIV infection. The right choice depends on information that may not appear on the latest liver-test report. ¹⁴

Entecavir has empty-stomach instructions, unlike some other HBV products. Ask the pharmacist how to fit the exact directions into your routine, rather than borrowing another person’s schedule. Kidney-related prescribing adjustments require professional assessment. As with other HBV antivirals, discontinuation can be followed by a hepatitis flare. A change of pharmacy, prescriber, or insurance should include a clear plan for continued supply and an opportunity to resolve instructions that seem inconsistent. ¹⁴

When peginterferon may be considered

Peginterferon alfa-2a offers a finite treatment approach for selected people, but its suitability differs from that of oral antiviral therapy. The assessment includes whether liver disease is compensated, meaning the liver is still maintaining its essential functions, and a review of psychiatric and autoimmune history. Decompensated cirrhosis is a contraindication in the US PEGASYS label. Blood counts and thyroid function are among the issues that require monitoring. A shorter planned course therefore does not mean an easier or safer choice for every patient. ¹⁵

Flu-like symptoms can occur, and serious neuropsychiatric or other systemic adverse effects are possible. Discuss mood changes, previous mental health conditions, and the practical demands of follow-up before choosing this approach. The team should explain what symptoms need prompt contact. Information about peginterferon combined with other drugs for hepatitis C should not be assumed to describe the same treatment plan as peginterferon used for hepatitis B. ¹⁵

How doctors judge whether treatment is working

Successful treatment is assessed over time, not from how a person feels after a few tablets. Long-term research with TDF found that sustained treatment could be accompanied by improvements in liver inflammation and fibrosis. Some participants with cirrhosis on an earlier biopsy no longer met the same histological definition on a later biopsy. That is encouraging evidence that controlling infection can have benefits beyond changing a blood-test number. It is not a promise that every person’s scarring will reverse. The study’s paired-biopsy analysis included only a subset of the original participants, and the follow-up design limits how its findings should be generalized. After an initial randomized comparison, participants entered an open-label phase, so the later observations were not a continuing blinded comparison of two treatments. The research was funded by the manufacturer. Those features should accompany the encouraging result when discussing what the study can establish. A biopsy improvement also should not be translated into permission to abandon clinical follow-up. Your team needs to consider the response of the virus and the condition of the liver together. ²⁰

An eight-year follow-up from the TAF and TDF trial program supports the possibility of durable viral suppression during continued therapy. Kidney and bone measurements were generally stable with TAF, and some changes seen during TDF treatment improved after participants switched. However, the original randomized comparison did not remain unchanged for all eight years: the later period involved an open-label extension, and not every original participant completed every assessment. Results also depend on how missing observations are handled. An analysis that counts a missing result as treatment failure answers a different question from one that excludes people without a result. Reporting only the higher percentage would conceal that distinction and could make the evidence appear more certain than it is. These details matter when reading claims that one medicine is always better or when comparing percentages from unrelated studies. Long follow-up can inform a treatment discussion, but it cannot predict an individual’s exact response or establish that liver-cancer risk has disappeared. Medicine selection still needs the person’s current history and safety assessment. ²¹

Can hepatitis B be cured? The October 2026 position

Viral suppression means treatment has controlled replication. Functional cure refers to sustained loss of surface antigen with viral control after treatment. It does not establish complete eradication of every trace of HBV from the liver. These terms describe different endpoints and should not be used interchangeably. ³

Japan approved Hibsago, or bepirovirsen, on 24 August 2026 for a restricted group of adults with chronic hepatitis B. Its October Japanese label requires prior and concomitant nucleos(t)ide analogue treatment and specific viral-marker criteria; it excludes all cirrhosis, including compensated cirrhosis. Treatment requires experienced specialist care and monitoring of liver tests, platelets, and kidney function. Functional cure occurred in a minority of eligible trial participants, so approval does not mean a guaranteed cure for everyone. Existing antivirals must not be stopped independently. As of this article’s 15 October 2026 check, no US FDA approval for bepirovirsen was located. The sponsor had announced priority review with a 26 October 2026 decision goal date, which is not a promise of approval. Japanese authorization does not establish access or eligibility in another country. Ask a specialist about current local availability rather than relying on a headline or a trial description. ²⁷

Monitoring and making treatment workable

A useful care plan explains the treatment goal, expected benefits, possible harms, and tests needed over time. Ask for a written version in language you understand. It should distinguish checks on viral response from safety monitoring and explain who will review results. Family-planning questions and concerns about long-term medicine use deserve space in that discussion. If a plan is difficult to follow, the reason may be cost, work hours, confusing directions, side effects, or worry about treatment. These are matters to address together rather than reasons to label someone uncooperative. A personalized discussion can identify which problem actually needs solving. Ask how to obtain advice between appointments, especially when another clinician proposes a medicine change or when your circumstances make the agreed schedule difficult. ¹⁷

Practical preparation helps keep a daily medicine routine from being interrupted. Keep the clinic and pharmacy contact details somewhere easy to find, know when the next refill is due, and raise a likely supply problem before the last tablet. Travel planning should include enough medicine and a way to clarify instructions if schedules change. Choose reminders that fit the product’s directions and your everyday life. If you miss doses, use the instructions for that particular medicine and ask the prescribing team when you are uncertain. Do not generalize a missed-dose rule from a different antiviral or double up on your own. Tell the team honestly about repeated missed doses so they can help you return to a safe plan. A routine works best when it is practical, understood, and supported by reliable access to treatment. ¹⁸

How long treatment lasts and why stopping needs a plan

An undetectable HBV DNA result while taking medicine is not, on its own, evidence that treatment can safely end. The RETRACT-B study followed people after withdrawal of nucleos(t)ide analogue therapy and documented serious outcomes, including liver decompensation. Cirrhosis increased the risk. Decompensation also occurred in the subgroup without cirrhosis that had received a consolidation period of treatment before stopping. Absence of cirrhosis therefore did not make withdrawal risk-free in this study. Because this was an observational cohort, its findings do not provide a universal stopping rule or predict what will happen to a particular person. They do show why stopping is a clinical decision with consequences beyond whether the next blood test detects virus. A supervised plan needs careful patient selection, access to follow-up, and a response if hepatitis returns. Do not test whether you still need treatment by taking a break between prescriptions. A negative viral-load result may reflect the medicine doing its job, and the team needs more information before deciding whether a finite course is appropriate. ²²

Oral treatment is often prolonged. Guideline approaches to planned withdrawal differ, with EASL allowing consideration in some carefully selected people without cirrhosis. This requires specialist supervision and follow-up; it is not a self-assessment checklist. ³

Pregnancy and the period after delivery

Pregnancy care separates treatment for the pregnant person’s liver health from antiviral prophylaxis intended to lower the chance of transmission at birth. If hepatitis B surface antigen is positive, HBV DNA assessment and coordination with the maternity and newborn teams matter. Infants born to surface-antigen-positive people need hepatitis B vaccine and hepatitis B immune globulin within 12 hours. Maternal antiviral treatment does not replace that protection. Make sure the delivery team has the test information and that infant follow-up is arranged. ⁴

Drug recommendations depend on the guideline. AASLD/IDSA’s 2025 guidance includes TDF or TAF, with more extensive pregnancy safety experience for TDF. Review pregnancy plans early, and arrange postpartum follow-up rather than assuming treatment ends at delivery. ²

WHO emphasizes TDF for prevention of mother-to-child transmission when its criteria are met. Learning you are pregnant is a reason for prompt review of an existing prescription, not an instruction to stop or switch it yourself. ¹

When HIV, hepatitis C, or hepatitis D changes the plan

Hepatitis B and HIV

When HIV and HBV occur together, treatment needs to control both infections within a fully suppressive HIV regimen. NIH guidance commonly uses tenofovir together with emtricitabine or lamivudine as part of that plan, while recognizing circumstances that require alternatives. Entecavir needs particular care because it must be accompanied by fully suppressive HIV treatment to avoid HIV resistance concerns. This is a prescribing decision for the treating team, not a reason to combine tablets independently. ⁶

An HIV regimen change should include an explicit check of what will continue treating HBV. Some long-acting HIV options do not themselves provide hepatitis B treatment, and removing HBV-active medicines can allow reactivation. Tell both teams about proposed switches, even when HIV is well controlled and the new option seems more convenient. Ask who will monitor liver tests and HBV DNA during the transition. The important point is continuity of effective care for both viruses, not simply whether a medicine is described as an antiviral. ⁶

Hepatitis B and hepatitis C

Before direct-acting antiviral treatment for hepatitis C, guidance calls for hepatitis B testing, including surface antigen, surface antibody, and core antibody. These markers help distinguish current infection from evidence of previous exposure or immunity. People who are surface-antigen positive also need HBV DNA assessment and an agreed management plan. That may involve HBV antiviral treatment or a monitoring strategy, depending on the findings. ⁷

The issue is that HBV can reactivate around hepatitis C treatment. It is a reason for coordination, not a reason to abandon an effective hepatitis C therapy. Ask which clinician is responsible for the hepatitis B plan and how test results will be reviewed during and after treatment. Successfully treating hepatitis C does not automatically clear hepatitis B, so the follow-up requirements for the two infections may differ. Do not interpret a hepatitis C cure result as permission to stop an HBV prescription. ⁷

Hepatitis B and hepatitis D

Hepatitis D requires its own assessment in someone with hepatitis B. EASL’s hepatitis delta guidance recommends antibody testing at least once in people who are hepatitis B surface-antigen positive, with HDV RNA testing to establish whether infection is active. Antibody and RNA results answer different questions: a screening result is not a complete measure of current viral activity. Ask whether testing has been done rather than assuming the usual HBV blood panel includes it. ¹⁰

HBV DNA measures hepatitis B viral activity; it does not measure hepatitis D. A low HBV DNA result therefore cannot, by itself, rule out active HDV. Oral medicines used for HBV may still be necessary, while a specialist considers separate HDV treatment. Keeping these purposes distinct helps explain why someone whose hepatitis B appears suppressed may still need further investigation or another treatment discussion. ¹⁰

On 22 May 2026, the US FDA approved Hepcludex, or bulevirtide-gmod, for chronic hepatitis D in adults without cirrhosis or with compensated cirrhosis. This is an HDV indication, not a general treatment claim for hepatitis B alone. Accelerated approval was based on HDV RNA reduction and ALT normalization; improvement in disease-related clinical outcomes has not been established, and confirmatory evidence remains important. The US label warns that stopping can cause severe acute flares of hepatitis D and B, especially with cirrhosis. It requires close monitoring after discontinuation. Serious allergic reactions are also a safety concern. A specialist needs to discuss suitability, the monitoring burden, and how underlying hepatitis B will continue to be managed. Approval in the United States does not establish the same access or labeling elsewhere, and it does not make an unsupervised treatment interruption safe. ²⁸

Preventing reactivation during other medical treatment

A previous hepatitis B infection can remain relevant before chemotherapy or immune-suppressing treatment, even if it is not currently causing symptoms. Reactivation risk depends on the HBV test pattern and the proposed treatment. A past-infection result does not by itself mean that someone has active hepatitis now. The purpose of assessment is to anticipate whether a change in immune control could allow viral activity to return. Different medicines and treatment combinations do not carry identical risks. ⁸

The AGA’s 2025 guideline distinguishes antiviral prophylaxis from monitoring. Higher-risk situations generally favor preventive medicine; other situations require a decision that weighs risk and whether reliable follow-up is feasible. If monitoring is chosen, HBV DNA matters alongside ALT. Ask which approach is planned, who is ordering the tests, and how results will be acted on. Prophylaxis means trying to prevent a problem before it occurs, whereas monitoring means actively looking for evidence that the plan needs to change. ⁸

Coordination with cancer care

ASCO recommends hepatitis B screening before systemic anticancer treatment using the three-part panel of surface antigen, core antibody, and surface antibody. Screening should be organized without unnecessarily delaying cancer therapy. The oncology and liver teams use the results to decide whether preventive treatment and follow-up are needed. This makes the history of an old hepatitis diagnosis important even when it has not caused recent problems. Give the team previous results if available, but do not postpone essential treatment while trying to interpret them yourself. ⁹

Chronic HBV and certain high-risk situations after past infection need particular attention. Anti-CD20 therapy and stem-cell transplantation are important examples in the cancer setting. Follow-up can extend beyond the active cancer-treatment period, so the handover between teams should identify who remains responsible. Ask for the plan in the treatment summary. A completed chemotherapy course is not automatically the end of hepatitis B prevention or monitoring. ⁹

Why liver-cancer surveillance may continue

Monitoring the amount of HBV in blood and looking for early liver cancer are different tasks. Antiviral suppression does not remove the need for cancer surveillance in people whose risk still meets guideline criteria. AASLD recommends ultrasound with alpha-fetoprotein, or AFP, approximately every six months for appropriate at-risk patients. Not everyone with hepatitis B has the same eligibility or imaging plan. Ask whether surveillance applies to you and which team is arranging it. ¹¹

An abnormal surveillance result may lead to further diagnostic imaging rather than immediately establishing a cancer diagnosis. An ultrasound that does not provide adequate views can also require a different approach. Conversely, a reassuring examination describes that assessment; it does not guarantee that future surveillance is unnecessary. Keep the imaging plan distinct from routine blood tests so that a good viral-load result does not accidentally become a reason to miss a scheduled scan. ¹¹

Advanced liver disease and urgent symptoms

Advanced liver disease may require evaluation for complications and, in some circumstances, liver transplantation. AASLD/AST guidance emphasizes urgent transplant-center assessment for acute liver failure. In chronic liver disease, decompensating complications can justify referral even when a single numerical score seems less severe. Referral is an assessment of potential benefit and suitability, not a guarantee of transplantation or an automatic commitment to surgery. It includes medical and psychosocial considerations, because the team needs to understand the whole situation and what support will be needed. ¹⁹

Ask what has prompted a referral and what question the transplant team is being asked to answer. The next steps may involve further assessment rather than an immediate procedure. Do not try to decide eligibility from an online score alone, or assume that continuing antiviral treatment makes an evaluation unnecessary. The specialist team considers the course of liver disease and its complications alongside the effects of treatment. ¹⁹

In someone with cirrhosis, new or worsening jaundice, swelling, or breathlessness warrants prompt medical attention. Sudden confusion, vomiting blood, or black stools require emergency care. These symptoms cannot safely be explained away because a recent viral-load result was good. Use the emergency service where you live when emergency signs occur, rather than waiting for the next liver appointment. The warning signs are reasons to seek assessment, not a home checklist that can confirm or exclude a particular complication. Tell the treating team about the known liver condition and current medicines when seeking help. ¹⁶

Liver health, supplements, and support

Milk thistle is often marketed for liver support, but evidence is insufficient to recommend it as a hepatitis B treatment. Studies of liver conditions have been limited or inconsistent, and a product’s marketing language does not establish that it controls HBV. Supplement quality, allergies, and interactions are also relevant. Tell your clinician or pharmacist exactly what you are considering, including the product and ingredients, so that the discussion is about the actual preparation. ²⁵

A supplement should not replace prescribed antiviral treatment or the tests used to monitor infection. “Natural” is not a clinical result, and improvement in how someone feels does not establish an antiviral effect. This does not mean every supplement is identical or that all are harmful; it means claims need evidence and the proposed product needs review in the context of your care. Be cautious about a product that asks you to abandon follow-up in favor of a promised cure. ²⁵

Living with hepatitis B can raise questions that are not answered by a prescription. A qualitative study of people seeking HBV information identified concerns about treatment, laboratory results, stigma, fear, and isolation. Those findings describe the experiences of the people whose inquiries were analyzed; they do not establish how common each concern is in everyone with HBV. They do underline the value of making room for questions that can otherwise remain unspoken. ²³

If you are worried about what a result means, ask for the explanation in ordinary language and say which part is still unclear. If stigma or isolation is making care harder, tell a trusted healthcare professional and ask about appropriate support. You do not need to present yourself as an expert in the infection to take part in treatment decisions. A useful consultation can address both the medical plan and the concerns that make living with that plan difficult. ²³

Questions to take to your next appointment

• Why do you recommend treatment or monitoring in my situation?
• Which results are you following, and when is my next review?
• What should I do about a missed dose, side effect, or refill problem?
• Who coordinates pregnancy planning, other treatments, and specialist follow-up?
• Do I need liver-cancer surveillance or testing for another hepatitis virus?

Frequently asked questions

Does acute hepatitis B always need antivirals?

No. Uncomplicated acute infection usually receives supportive care. Severe disease needs specialist assessment. ⁴

Is Hibsago available worldwide?

Japan’s approval does not establish availability elsewhere. ²⁷

Can monitoring continue when HBV is suppressed?

Yes. People who meet liver-cancer risk criteria still need surveillance. ¹¹

Can milk thistle replace hepatitis B treatment?

No. Evidence does not support using it instead of prescribed care. ²⁵

The original educational video is retained below. Its full content has not been reviewed for this update and may predate current guidance. Use the dated written article and your care team for current treatment decisions.